Novartis Fact Sheet
About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development.
Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 145 nationalities work at Novartis around the world.
Company headquarters
|
|
Novartis International AG
|
Share monitor
Q2 2020 results
| Continuing operations1 | Q2 2020 (USD m) |
Q2 2019 (USD m) |
% change (USD) |
|---|---|---|---|
| Net sales | 11,347 | 11,764 | -4 |
2019 annual results
| Continuing operations2 | FY 2019 (USD m) |
FY 2018 (USD m) |
% change (USD) |
|---|---|---|---|
| Net sales | 47,445 | 44,751 | 6 |
Find annual, quarterly results and more in our financial data section
- Refers to continuing operations as defined on page 42 of the Q2 2020 Condensed Interim Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz, as well as the continuing corporate functions.
- Refers to continuing operations as defined on page 45 of the Q4 2019 Condensed Financial Report, excludes Alcon, includes the businesses of Innovative Medicines and Sandoz (including the US generic oral solids and dermatology portfolio), as well as the continuing corporate functions.
Chief Executive Officer
 |
Vasant (Vas) Narasimhan, M.D.
|
Corporate Responsibility
Access to healthcare
- Through our business, we make an important contribution to society: We discover and develop innovative healthcare products, targeting unmet medical needs. Novartis medicines reach nearly 800 million people each year.
- In 2019, our access-to-healthcare programs reached 16 million patients with Novartis products and 10 million people with training and health education programs.
Our complementary healthcare businesses address the changing needs of patients and societies worldwide. With innovative pharmaceuticals at the core, we are also global leader in generic pharmaceuticals and biosimilars
Top Innovative Medicines products
| Brands | Full Year 2019 Product Sales | Franchise | |
|---|---|---|---|
| Net Sales (USD m) | variance in USD | ||
| Cosentyx | 3,551 | 25% | Immunology, Hepatology & Dermatology |
| Gilenya | 3,223 | -4% | Neuroscience |
| Lucentis | 2,086 | 2% | Ophthalmology |
| Tasigna | 1,880 | 0% | Oncology |
| Entresto | 1,726 | 68% | Cardiovascular, Renal and Metabolism |
Novartis #3 corporate institution in Nature Index 2018 ranking
The Nature Index 2018 ranking, published by Nature Research, ranks various institutions (corporate, academic, government, NPO/NGO) based on contributions to articles published in a group of 82 selected science journals. Novartis maintained its #3 ranking from 2017.
Novartis ranks #3 in 2018 Pharmaceutical Innovation Index
IdeaPharma’s PII ranks companies on their ability to bring products from early development to market and commercialize them successfully. Novartis moved up 9 spots, from #12 in 2017.
Novartis moves up 4 places to 64 in 2018 Global 100 Most Sustainable Corporations list by Corporate Knights
The Corporate Knights list is recognized as one of the leading sustainability rankings worldwide and inclusion is determined using up to 14 quantitative social, environmental and governance indicators, such as innovation capacity, employee turnover and leadership diversity.
Fast Company’s 2018 World's Most Innovative Companies list
Novartis has been named #1 most innovative biotech company and ranked #21 overall by Fast Company. The ranking identifies the most notable innovations of the year.
Fortune's Most Admired Pharmaceutical Companies 2018
Novartis has been ranked #3 by Fortune magazine as one of the most admired pharmaceutical companies in the world — our 14th consecutive year in the top three.
CDP rates Novartis A on Water and A- in Climate in 2017
Novartis is one of 73 companies worldwide to make CDP’s Water A List in 2017. We also maintained an A- rating and are recognized among category leaders in healthcare in the 2017 CDP Climate Score.
Fortune’s Change the World List 2017
Novartis ranked #4 in Fortune’s list of companies that are doing well by doing good. The list recognizes companies that have a positive social impact through activities that are part of their core business strategy.
| For further information regarding Novartis please contact: | |||||||||
|
|
||||||||
|
|
||||||||